Azacitidine and venetoclax (AZA/VEN) for older adults with AML ineligible for intensive chemother...

Azacitidine and venetoclax (AZA/VEN) for older adults with AML ineligible for intensive chemotherapy  Penn Medicine

Efficacy and Safety of First-Line Acalabrutinib Plus Venetoclax Revamps QOL Outcomes in CLL - Onc...

Efficacy and Safety of First-Line Acalabrutinib Plus Venetoclax Revamps QOL Outcomes in CLL  OncLive

Venetoclax Combination Therapy Shows Promising Activity in Relapsed AML - Inside Precision Medicine

Venetoclax Combination Therapy Shows Promising Activity in Relapsed AML  Inside Precision Medicine

HMA/Venetoclax Is Superior to Intensive Chemo in Fit Patients With AML - Targeted Oncology

HMA/Venetoclax Is Superior to Intensive Chemo in Fit Patients With AML  Targeted Oncology

Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for pa...

Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukaemia in the 1st-line setting  AstraZeneca

A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia - Nature

A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia  Nature

FDA Approves Venetoclax (Venclexta) Plus Acalabrutinib (Calquence) for Previously Untreated CLL -...

FDA Approves Venetoclax (Venclexta) Plus Acalabrutinib (Calquence) for Previously Untreated CLL  Oncology News Central

CLL/SLL: FDA Approves Combination of Acalabrutinib and Venetoclax - The ASCO Post

CLL/SLL: FDA Approves Combination of Acalabrutinib and Venetoclax  The ASCO Post

New All-Oral CLL Regimen Offers Fixed-Duration Treatment Option - Cure Today

New All-Oral CLL Regimen Offers Fixed-Duration Treatment Option  Cure Today

Practical Considerations for Integrating Zanubrutinib Plus Venetoclax in CLL Therapy - CancerNetwork

Practical Considerations for Integrating Zanubrutinib Plus Venetoclax in CLL Therapy  CancerNetwork

Dr Brown on QOL Considerations With Frontline Acalabrutinib/Venetoclax in CLL - OncLive

Dr Brown on QOL Considerations With Frontline Acalabrutinib/Venetoclax in CLL  OncLive

Impact of venetoclax trough levels on safety and efficacy in the treatment of acute myeloid leuke...

Impact of venetoclax trough levels on safety and efficacy in the treatment of acute myeloid leukemia  Nature

Zanubrutinib/Venetoclax Continues to Impress in Treatment-Naive CLL/SLL - Targeted Oncology

Zanubrutinib/Venetoclax Continues to Impress in Treatment-Naive CLL/SLL  Targeted Oncology

FDA Approves First-Line Acalabrutinib Plus Venetoclax for CLL/SLL - OncLive

FDA Approves First-Line Acalabrutinib Plus Venetoclax for CLL/SLL  OncLive

Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetocl...

Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetoclax plus hypomethylating agents: a real-world, multicentric study | Blood Cancer Journal  Nature

FDA Approves Acalabrutinib Plus Venetoclax for Previously Untreated CLL/SLL - Targeted Oncology

FDA Approves Acalabrutinib Plus Venetoclax for Previously Untreated CLL/SLL  Targeted Oncology

Dr Shadman on Indirect Data for Zanubrutinib vs Acalabrutinib/Venetoclax in Treatment-Naive CLL -...

Dr Shadman on Indirect Data for Zanubrutinib vs Acalabrutinib/Venetoclax in Treatment-Naive CLL  OncLive

The combination of venetoclax with dimethyl fumarate synergistically induces apoptosis in AML cel...

The combination of venetoclax with dimethyl fumarate synergistically induces apoptosis in AML cells by disrupting mitochondrial integrity through ROS accumulation  Nature

Dr Lamanna on the FDA Approval of Acalabrutinib Plus Venetoclax for CLL - OncLive

Dr Lamanna on the FDA Approval of Acalabrutinib Plus Venetoclax for CLL  OncLive

Venetoclax Plus Azacitidine Misses OS End Point in Newly Diagnosed Higher-Risk MDS - OncLive

Venetoclax Plus Azacitidine Misses OS End Point in Newly Diagnosed Higher-Risk MDS  OncLive

Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute my...

Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia: a multicenter phase 2 trial | Blood Cancer Journal  Nature

FDA OKs Acalabrutinib/Venetoclax in CLL/SLL - Oncology Nursing News

FDA OKs Acalabrutinib/Venetoclax in CLL/SLL  Oncology Nursing News

Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a mul...

Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial  The Lancet

Nemtabrutinib With Venetoclax Shows Promising Activity in R/R CLL/SLL - OncLive

Nemtabrutinib With Venetoclax Shows Promising Activity in R/R CLL/SLL  OncLive

BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1 -rearranged acute myeloid leukemi...

BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1 -rearranged acute myeloid leukemia  Nature

Fixed-Duration Venetoclax Plus Obinutuzumab Yields High CR Rates, Manageable Safety in CLL/SLL - ...

Fixed-Duration Venetoclax Plus Obinutuzumab Yields High CR Rates, Manageable Safety in CLL/SLL  OncLive

Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML - The American Journal...

Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML  The American Journal of Managed Care® (AJMC®)

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified...

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model  Nature

Modified Venetoclax Dose Outperforms Standard Care in Unfit AML Patients - The American Journal o...

Modified Venetoclax Dose Outperforms Standard Care in Unfit AML Patients  The American Journal of Managed Care® (AJMC®)

Venetoclax resistance in preclinical KMT2A-rearranged acute lymphoblastic leukemia models is char...

Venetoclax resistance in preclinical KMT2A-rearranged acute lymphoblastic leukemia models is characterized by high inter- and intra-model heterogeneity  Nature

Acalabrutinib With Venetoclax Approved for Previously Untreated CLL, SLL - Medical Professionals ...

Acalabrutinib With Venetoclax Approved for Previously Untreated CLL, SLL  Medical Professionals Reference

Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase...

Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib  Nature

Digital twin models for predicting venetoclax and azacitidine-induced neutropenia in patients wit...

Digital twin models for predicting venetoclax and azacitidine-induced neutropenia in patients with acute myeloid leukemia  Nature

Late Addition of Obinutuzumab to Acalabrutinib/Venetoclax Maintains Responses, Boosts Safety in T...

Late Addition of Obinutuzumab to Acalabrutinib/Venetoclax Maintains Responses, Boosts Safety in Treatment-Naive CLL  OncLive

FDA Approves Venetoclax Plus Acalabrutinib for Previously Untreated Adults With CLL - Pharmacy Times

FDA Approves Venetoclax Plus Acalabrutinib for Previously Untreated Adults With CLL  Pharmacy Times

Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsin...

Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsing after allogeneic HSCT | Bone Marrow Transplantation  Nature

Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid...

Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia  Nature

Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resista...

Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies | Leukemia  Nature

Venetoclax/Obinutuzumab Is a Cost-Effective Treatment Option for CLL - Targeted Oncology

Venetoclax/Obinutuzumab Is a Cost-Effective Treatment Option for CLL  Targeted Oncology

Venetoclax + acalabrutinib approved by the FDA for previously untreated CLL - Lymphoma Hub

Venetoclax + acalabrutinib approved by the FDA for previously untreated CLL  Lymphoma Hub

FDA Review Underway for Oral Venetoclax, Acalabrutinib Combo in Untreated CLL - Targeted Oncology

FDA Review Underway for Oral Venetoclax, Acalabrutinib Combo in Untreated CLL  Targeted Oncology

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation fo...

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia  Nature

Fixed-Duration Ibrutinib/Venetoclax Shows Durable Responses in CLL, Says Dr Ghia - Targeted Oncology

Fixed-Duration Ibrutinib/Venetoclax Shows Durable Responses in CLL, Says Dr Ghia  Targeted Oncology

Clinical Utility of Early Bone Marrow Biopsy During Venetoclax Plus Hypomethylating Agent Therapy...

Clinical Utility of Early Bone Marrow Biopsy During Venetoclax Plus Hypomethylating Agent Therapy in Acute Myeloid Leukemia  Cancer Therapy Advisor

A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-r...

A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia  Wiley Online Library

What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with C...

What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with CLL?  Lymphoma Hub

The Evolving Role of Retreatment With Venetoclax-Based Regimens in CLL - OncLive

The Evolving Role of Retreatment With Venetoclax-Based Regimens in CLL  OncLive

Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute pr...

Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia  Nature

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidin...

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net | Blood Cancer Journal  Nature

Remote-controlled CAR-T cells use venetoclax to disengage from tumors - Medical Xpress

Remote-controlled CAR-T cells use venetoclax to disengage from tumors  Medical Xpress

Dr Brown on Notable Design Features of the AMPLIFY Trial in CLL - OncLive

Dr Brown on Notable Design Features of the AMPLIFY Trial in CLL  OncLive

Zanubrutinib Shows Superior PFS vs Venetoclax/Obinutuzumab in Indirect Comparison of Treatment-Na...

Zanubrutinib Shows Superior PFS vs Venetoclax/Obinutuzumab in Indirect Comparison of Treatment-Naive CLL  OncLive

In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Compar...

In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison  The American Journal of Managed Care® (AJMC®)

Acalabrutinib/Venetoclax sNDA Under FDA Review for Previously Untreated CLL - OncLive

Acalabrutinib/Venetoclax sNDA Under FDA Review for Previously Untreated CLL  OncLive

Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML -...

Revumenib Plus Decitabine/Cedazuridine and Venetoclax Proves Efficacious in Newly Diagnosed AML  OncLive

Venetoclax Combo Shows High Efficacy, Manageable Safety in First-Line CLL and SLL - Targeted Onco...

Venetoclax Combo Shows High Efficacy, Manageable Safety in First-Line CLL and SLL  Targeted Oncology

Long-Term Data Support Venetoclax Plus Rituximab in Relapsed/Refractory CLL - OncLive

Long-Term Data Support Venetoclax Plus Rituximab in Relapsed/Refractory CLL  OncLive

Venetoclax-Based Therapy in AML: Benefits, Toxicity, and Real-World Adjustments - OncLive

Venetoclax-Based Therapy in AML: Benefits, Toxicity, and Real-World Adjustments  OncLive

Factors affecting response and resistance to venetoclax in acute myeloid leukemia - Frontiers

Factors affecting response and resistance to venetoclax in acute myeloid leukemia  Frontiers

mTOR inhibition sensitizes T-ALL cells to Venetoclax through engagement of the integrated stress ...

mTOR inhibition sensitizes T-ALL cells to Venetoclax through engagement of the integrated stress response  Nature

FDA Reviews All-Oral Decitabine/Cedazuridine/Venetoclax Combo in AML - Targeted Oncology

FDA Reviews All-Oral Decitabine/Cedazuridine/Venetoclax Combo in AML  Targeted Oncology

Decitabine/Cedazuridine Plus Venetoclax sNDA Under FDA Review for Newly Diagnosed AML - OncLive

Decitabine/Cedazuridine Plus Venetoclax sNDA Under FDA Review for Newly Diagnosed AML  OncLive

Fixed-duration ibrutinib–venetoclax with MRD-guided ibrutinib–obinutuzumab intensification in fir...

Fixed-duration ibrutinib–venetoclax with MRD-guided ibrutinib–obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial  The Lancet

Fixed-Duration Venetoclax (Venclexta) Matches Continuous Ibrutinib (Imbruvica) in Frontline CLL -...

Fixed-Duration Venetoclax (Venclexta) Matches Continuous Ibrutinib (Imbruvica) in Frontline CLL  Oncology News Central

Zanubrutinib Extends PFS vs Acalabrutinib Plus Venetoclax in Untreated, Low-Risk CLL - OncLive

Zanubrutinib Extends PFS vs Acalabrutinib Plus Venetoclax in Untreated, Low-Risk CLL  OncLive

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML:...

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study  Nature

FDA Grants Breakthrough Status to ICT01 Plus Venetoclax/Azacitidine in AML - Targeted Oncology

FDA Grants Breakthrough Status to ICT01 Plus Venetoclax/Azacitidine in AML  Targeted Oncology

Venetoclax and the Impact on Management of Older Patients With AML - The American Journal of Mana...

Venetoclax and the Impact on Management of Older Patients With AML  The American Journal of Managed Care® (AJMC®)

VERONA Trial Misses Primary End Point of OS Benefit With Azacitidine/Venetoclax in Higher-Risk MD...

VERONA Trial Misses Primary End Point of OS Benefit With Azacitidine/Venetoclax in Higher-Risk MDS  OncLive

Rapid response to obinutuzumab and venetoclax in patients with nephrotic syndrome related to CLL:...

Rapid response to obinutuzumab and venetoclax in patients with nephrotic syndrome related to CLL: a report of two cases  Frontiers

Ibrutinib–Venetoclax Outperforms Ibrutinib Alone and FCR in Long-Term CLL - Pharmacy Times

Ibrutinib–Venetoclax Outperforms Ibrutinib Alone and FCR in Long-Term CLL  Pharmacy Times

Zanubrutinib/Venetoclax Demonstrates Robust Efficacy in CLL/SLL - CancerNetwork

Zanubrutinib/Venetoclax Demonstrates Robust Efficacy in CLL/SLL  CancerNetwork

Fixed-Duration Ibrutinib Plus Venetoclax Demonstrates Long-Term Efficacy in Untreated CLL/SLL - O...

Fixed-Duration Ibrutinib Plus Venetoclax Demonstrates Long-Term Efficacy in Untreated CLL/SLL  OncLive

Venetoclax-Based Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia - The ASCO Post

Venetoclax-Based Therapy for Patients With Newly Diagnosed Acute Myeloid Leukemia  The ASCO Post

Real-World Data Highlight Feasibility of Venetoclax Plus Obinutuzumab In First-Line CLL With Como...

Real-World Data Highlight Feasibility of Venetoclax Plus Obinutuzumab In First-Line CLL With Comorbidities  OncLive

Azacitidine Plus Venetoclax Shows Superior Efficacy Compared With Intensive Chemotherapy for Newl...

Azacitidine Plus Venetoclax Shows Superior Efficacy Compared With Intensive Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia  HMP Global Learning Network

Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple M...

Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway  Wiley

Venetoclax-Enhanced RBAC Shows Promise in High-Risk Mantle Cell Lymphoma - OncLive

Venetoclax-Enhanced RBAC Shows Promise in High-Risk Mantle Cell Lymphoma  OncLive

Zanubrutinib/Venetoclax Yields Deep Responses in Treatment-Naive CLL Regardless of Del17p/TP53 Mu...

Zanubrutinib/Venetoclax Yields Deep Responses in Treatment-Naive CLL Regardless of Del17p/TP53 Mutational Status  OncLive

Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk fo...

Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403 | Blood Cancer Journal  Nature

Venetoclax Effective in Older Patients With CLL - The American Journal of Managed Care® (AJMC®)

Venetoclax Effective in Older Patients With CLL  The American Journal of Managed Care® (AJMC®)

Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemi...

Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia  Nature

Pharmac to fund two medicine combinations for chronic lymphocytic leukaemia - RNZ

Pharmac to fund two medicine combinations for chronic lymphocytic leukaemia  RNZ

AbbVie, Roche's venetoclax duo fails in late-stage MDS study - FirstWord Pharma

AbbVie, Roche's venetoclax duo fails in late-stage MDS study  FirstWord Pharma

MRD-guided treatment with ibrutinib + venetoclax: Updates from the FLAIR trial - Lymphoma Hub

MRD-guided treatment with ibrutinib + venetoclax: Updates from the FLAIR trial  Lymphoma Hub

R )-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venet...

R )-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venetoclax-resistant AML through MCL-1 downregulation  Nature

Higher Infection Risk With Venetoclax-Obinutuzumab vs Zanubrutinib in CLL/SLL - The American Jour...

Higher Infection Risk With Venetoclax-Obinutuzumab vs Zanubrutinib in CLL/SLL  The American Journal of Managed Care® (AJMC®)

‘Profound’ data show azacitidine plus venetoclax significantly benefits patients with AML - Healio

‘Profound’ data show azacitidine plus venetoclax significantly benefits patients with AML  Healio

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypometh...

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations | Blood Cancer Journal  Nature

Final analysis of the GAIA/CLL13 trial: Venetoclax combinations vs chemoimmunotherapy in CLL - Ly...

Final analysis of the GAIA/CLL13 trial: Venetoclax combinations vs chemoimmunotherapy in CLL  Lymphoma Hub

European Commission approves fixed-duration acalabrutinib + venetoclax ± obinutuzumab for adult p...

European Commission approves fixed-duration acalabrutinib + venetoclax ± obinutuzumab for adult patients with previously untreated CLL  Lymphoma Hub

Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagno...

Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial  Nature

AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acal...

AbbVie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)  PR Newswire

Chinese population may require further venetoclax dose reduction beyond guidelines when combined ...

Chinese population may require further venetoclax dose reduction beyond guidelines when combined with voriconazole: real-world evidence from China  Frontiers

Venetoclax/azacitidine for the treatment of acute myeloid leukemia: real-life experience prospect...

Venetoclax/azacitidine for the treatment of acute myeloid leukemia: real-life experience prospective single center study  Via Medica Journals

MRD-Guided Therapy With Ibrutinib/Venetoclax or Ibrutinib Alone in Chronic Lymphocytic Leukemia -...

MRD-Guided Therapy With Ibrutinib/Venetoclax or Ibrutinib Alone in Chronic Lymphocytic Leukemia  The ASCO Post

MDS subtype associated with poor outcomes after venetoclax-based therapy - UT MD Anderson

MDS subtype associated with poor outcomes after venetoclax-based therapy  UT MD Anderson

Novel CLL Therapies Prompt New Treatment Considerations - The American Journal of Managed Care® (...

Novel CLL Therapies Prompt New Treatment Considerations  The American Journal of Managed Care® (AJMC®)

Decitabine-Cedazuridine Plus Venetoclax Therapy Shows Efficacy and Safety for Patients With Newly...

Decitabine-Cedazuridine Plus Venetoclax Therapy Shows Efficacy and Safety for Patients With Newly Diagnosed AML  HMP Global Learning Network

SEQUOIA Arm D results: Zanubrutinib + venetoclax in patients with TN CLL/SLL - Lymphoma Hub

SEQUOIA Arm D results: Zanubrutinib + venetoclax in patients with TN CLL/SLL  Lymphoma Hub